Is Brii Biosciences Limited (BRIBF) a Buy, Sell, or Hold?
OTC : BRIBF
Brii Biosciences Limited — News
$0.12575 USD
$0 (0.0%)
- Volume
- 4.15K
- Average Volume
- 238
- Market Capitalization
- $90.69M
- P/E Ratio
- -2.77
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $0.25
- Year Low
- $0.13
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $60.73
| Source | Headline |
|---|---|
|
Brii Bio Presents Late-Breaking Data from Its Phase 2 ENSURE Study at EASL Congress 2026, Further Supporting the Potential Role of BRII-179 in Achieving Durable Immunological Control of HBV
- Final results from the ENSURE study demonstrate that the addition of elebsiran resulted in a higher functional cure rate compared with pegylated interferon alfa (PEG-IFNα) alone - Data from Cohort 4 suggested that participants responding to prior BRII ‑ 179 treatment achieved the most robust functional cure outcomes, further supporting its potential clinical benefit - Data from an ENSURE translational study demonstrated that BRII ‑ 179-induced epitope-mismatched CD4+ T cells and HBs ‑ specific B cell maturation were associated with enhanced HBsAg loss following curative treatment, offering additional insights into its potential mechanisms DURHAM, N.C. and BEIJING, May 27, 2026 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet medical need, today announced end-of-study (EOS) data from Cohorts 1-4 of its Phase 2 ENSURE study at the European Association for the Study of the Liver (EASL) Congress 2026 in Barcelona, Spain. prnewswire.com - 2026-05-27 07:00:00 |
